Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines
Authors:
- 1 March 1992
- journal article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 35 (2) , 135-144
Abstract
The antitumor effects of chemotherapy, recombinant human interleukin-2 (IL-2), recombinant human interferon α A/D (IFNα), allogeneic human lymphokine-activated killer (LAK) cells, and antitumor monoclonal antibody (mAb), administered alone and in various combinations, were tested in athymic nude mice carrying human tumor xenografts. Treatment began 6–18 days after i.v. or i.p. inoculation of colorectal carcinoma or melanoma cell lines, when macroscopic growths were evident. Chemotherapy consisted of two or three courses of 5-fluorouracil (5-FU) or dacarbazine. IL-2 and/or IFNα were administered three to five times weekly for 1–3 weeks, usually starting 2–5 days after chemotherapy. Human LAK cells were infused once or twice weekly for 2 or 3 weeks concurrently with IL-2. In some experiments, murine anticolorectal carcinoma mAb (SF25) was administered. In both tumor systems, chemotherapy alone or immunotherapy alone (IL-2, IL-2 + LAK cells, IFNα, IL-2 + IFNα ± LAK cells) had little or no therapeutic effects. Additive effects were obtained by combining chemotherapy with IL-2 and LAK cells or with IL-2 and IFNα. In the majority of the experiments, the most effective combination was chemotherapy + IL-2 + IFNα + LAK cells. Treatment with mAb was beneficial in the colorectal carcinoma system when combined with 5-FU + IL-2 or 5-FU + IL-2 + IFNα. Homing experiments with radiolabeled human and mouse LAK cells injected i.v. showed increased early accumulation in the liver and lungs, whereas freshly explanted mouse splenocytes localized mostly in the spleen and liver. The tissue distribution pattern of human LAK cells was similar in normal and tumor-bearing mice (with lung metastases). These findings suggest that combination of chemotherapy with cytokines and LAK cells can be partially effective for advanced solid human tumors even in the absence of the host's T-cell immune response. Preliminary experiments showed that tumor-specific, anti-melanoma T-cell clones were effective in local (s.c.) tumor growth inhibition (Winn assay) following coinjection with the autologous tumor cells.Keywords
This publication has 61 references indexed in Scilit:
- Chemo-Immunotherapy of murine solid tumors: Enhanced therapeutic effects by interleukin-2 combined with interferon α and the role of specific T cellsCancer Immunology, Immunotherapy, 1992
- In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing ratsCellular Immunology, 1990
- High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell CarcinomaJNCI: Journal of the National Cancer Institute, 1990
- Tumor‐specific T‐cell clones recognize different protein determinants of autologous human malignant melanoma cellsInternational Journal of Cancer, 1990
- Influence of interferon on adriamycin uptake of cultured tumor cellsInternational Journal of Cancer, 1989
- Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clonesEuropean Journal of Immunology, 1988
- In vivo anti‐tumor activity of combinations of interferon alpha and interleukin‐2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cellsInternational Journal of Cancer, 1987
- Production of stable cytolytic T‐cell clones directed against autologous human melanomaInternational Journal of Cancer, 1987
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- A rapid technique for isolation of viable tumor cells from solid tumors: Use of the tumor cells for induction and measurement of cell-mediated cytotoxic responsesEuropean Journal of Cancer and Clinical Oncology, 1982